Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (TDAC) is a blank-check special purpose acquisition company focused on the life sciences and translational medicine sector, with warrant securities registered under the ticker TDACW. The company filed an S-1/A amendment with the SEC on November 20, 2024, under accession number 0001104659-24-120690, advancing the registration process for its securities offering. The SPAC is structured to pursue a merger or acquisition target within the healthcare and biopharma space, with sponsor identity and offering terms outlined in the underlying registration materials on file with the commission. Sign up at SpacDesk to access full filing history, sponsor profiles, and deal timelines for TDAC and the broader SPAC market.